BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18446607)

  • 1. PLGA microspheres for the delivery of a novel subunit TB vaccine.
    Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y
    J Drug Target; 2008 May; 16(4):282-93. PubMed ID: 18446607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres.
    Kirby DJ; Rosenkrands I; Agger EM; Andersen P; Coombes AG; Perrie Y
    J Drug Target; 2008 Aug; 16(7):543-54. PubMed ID: 18686124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
    Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.
    Wang C; Muttil P; Lu D; Beltran-Torres AA; Garcia-Contreras L; Hickey AJ
    AAPS J; 2009 Mar; 11(1):139-47. PubMed ID: 19277872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation.
    Uchida T; Goto S; Foster TP
    J Pharm Pharmacol; 1995 Jul; 47(7):556-60. PubMed ID: 8568620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system.
    McNeil SE; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Sci; 2011 May; 100(5):1856-65. PubMed ID: 21374619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing solid particulate vaccine adjuvants: surface bound antigen favours a humoural response, whereas entrapped antigen shows a tendency for cell mediated immunity.
    Kirby DJ; Kaur R; Agger EM; Andersen P; Bramwell VW; Perrie Y
    Curr Drug Deliv; 2013 Jun; 10(3):268-78. PubMed ID: 23410072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
    Henriksen-Lacey M; Devitt A; Perrie Y
    J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
    Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
    Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens.
    Kofler N; Ruedl C; Klima J; Recheis H; Böck G; Wick G; Wolf H
    J Immunol Methods; 1996 Jun; 192(1-2):25-35. PubMed ID: 8699019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
    Ashhurst AS; Parumasivam T; Chan JGY; Lin LCW; Flórido M; West NP; Chan HK; Britton WJ
    PLoS One; 2018; 13(3):e0194620. PubMed ID: 29554138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
    Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
    Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of a model nucleoside (guanosine) release from biodegradable poly(DL-lactide-co-glycolide) microspheres: a delivery system for long-term intraocular delivery.
    Chowdhury DK; Mitra AK
    Pharm Dev Technol; 2000; 5(2):279-85. PubMed ID: 10810757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
    Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB
    J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice.
    Cai H; Hu XD; Yu DH; Li SX; Tian X; Zhu YX
    Vaccine; 2005 Jul; 23(32):4167-74. PubMed ID: 15908060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach.
    Rose F; Wern JE; Ingvarsson PT; van de Weert M; Andersen P; Follmann F; Foged C
    J Control Release; 2015 Jul; 210():48-57. PubMed ID: 25957906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide) microspheres using a modified water-in-oil-in-water (w/o/w) emulsion solvent evaporation technique.
    Zhu KJ; Jiang HL; Du XY; Wang J; Xu WX; Liu SF
    J Microencapsul; 2001; 18(2):247-60. PubMed ID: 11253941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study.
    Uchida T; Goto S
    Biol Pharm Bull; 1994 Sep; 17(9):1272-6. PubMed ID: 7841952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.